Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Clinical Requirements Regarding In Silico Oncology

Share :
Published: 23 Jan 2009
Views: 11542
Rating:
Save
Professor Norbert Graf, Director of Oncology and Haematology Clinic, University of Saarland
Lecture from the European Union ICT BIO 2008 Conference (Oct. 23-24, 2008) on Clinical Requirements Regarding In Silico Oncology

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Jill Corre - IUCT Oncopole, Toulouse, France
New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )
29 Oct 2024
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...
Dr Jill Corre - IUCT Oncopole, Toulouse, France
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )
29 Oct 2024
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...
Prof Xavier Leleu - CHU de Poitiers, Poitiers, France
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )
28 Oct 2024
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024
Use of bispecifics and CAR T cells in South America
Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )
28 Oct 2024
Revolutionising myeloma treatment through immune profiling
Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA
Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )
28 Oct 2024
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Prof Joy Ho - The University of Sydney, Sydney, Australia
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )
28 Oct 2024
Guiding transplant decisions in multiple myeloma with MRD
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )
28 Oct 2024
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )
28 Oct 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation